Impact of telomere length on survival in classic and variant hairy cell leukemia

被引:8
|
作者
Arons, Evgeny [1 ]
Zhou, Hong [1 ]
Edelman, Daniel C. [2 ]
Gomez, Allison [2 ]
Steinberg, Seth M. [3 ]
Petersen, David [2 ]
Wang, Yonghong [2 ]
Meltzer, Paul S. [2 ]
Kreitman, Robert J. [1 ]
机构
[1] NCI, Mol Biol Lab, NIH, Bethesda, MD 20892 USA
[2] NCI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA
[3] NCI, Biostat & Data Management Sect, Off Clin Director, Ctr Canc Res,NIH, Bethesda, MD 20892 USA
关键词
Telomere; Hairy cell leukemia; Molecular marker; Chromosomes; DNA damage; CHRONIC LYMPHOCYTIC-LEUKEMIA; LYMPHOPROLIFERATIVE DISORDERS; MYELOID-LEUKEMIA; FOLLOW-UP; DIAGNOSIS; CLADRIBINE; DYSFUNCTION; MUTATIONS; HISTOPATHOGENESIS; INSTABILITY;
D O I
10.1016/j.leukres.2015.09.015
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Telomeres, which protect the ends of chromosomes, are shortened in several hematologic malignancies, often with adverse prognostic implications, but their effect on prognosis of classic and variant hairy cell leukemia (HCL and HCLv) has not been reported. HCL/HCLv genomic DNA from 46 patients was studied by PCR to determine the ratio of telomere to single copy gene number (T/S). T/S was unrelated to diagnosis of HCL or HCLv (p = 0.27), but shorter T/S was associated with unmutated immunoglobulin rearrangements (p = 0.033) and age above the median at diagnosis (p = 0.017). Low T/S was associated with shorter overall survival from diagnosis (OS), particularly T/S <0.655 (p = 0.0064, adjusted p = 0.019). Shorter OS was also associated with presence of unmutated (p <0.0001) or IGHV4-34+ (p <0.0001) rearrangements, or increasing age (p = 0.0002). Multivariable analysis with Cox modeling showed that short T/S along with either unmutated or IGHV4-34+ rearrangements remained associated with reduced OS (p = 0.0071, p = 0.0024, respectively) after age adjustment. While T/S is relatively long in HCL and the disease usually indolent with excellent survival, shortened telomeres in HCL/HCLv are associated with decreased survival. Shortened T/S could represent a risk factor needing further investigation/intervention to determine if non-chemotherapy treatment options, in addition to or instead of chemotherapy, might be particularly useful. Published by Elsevier Ltd.
引用
收藏
页码:1360 / 1366
页数:7
相关论文
共 50 条
  • [31] Novel therapeutics in the treatment of hairy cell leukemia variant
    Letendre, Paul
    Doll, Donald
    LEUKEMIA RESEARCH, 2018, 75 : 58 - 60
  • [32] T-LYMPHOCYTE VARIANT OF HAIRY CELL LEUKEMIA
    SAXON, A
    STEVENS, RH
    GOLDE, DW
    BLOOD, 1977, 50 (05) : 175 - 175
  • [33] Successful treatment of hairy cell leukemia variant with obinutuzumab
    Al-Sarayfi, Diana
    Meeuwes, Freek O.
    Munnink, Thijs Oude
    Plattel, Wouter
    Rosati, Stefano
    Matutes, Estella
    Nijland, Marcel
    ANNALS OF HEMATOLOGY, 2022, 101 (03) : 703 - 704
  • [34] Successful treatment of hairy cell leukemia variant with rituximab
    Narat, S
    Gandla, J
    Dogan, A
    Mehta, A
    LEUKEMIA & LYMPHOMA, 2005, 46 (08) : 1229 - 1232
  • [35] Ibrutinib for relapsed refractory hairy cell leukemia variant
    Bohn, Jan-Paul
    Wanner, David
    Steurer, Michael
    LEUKEMIA & LYMPHOMA, 2017, 58 (05) : 1224 - 1226
  • [36] Successful treatment of hairy cell leukemia variant with obinutuzumab
    Diana Al-Sarayfi
    Freek O. Meeuwes
    Thijs Oude Munnink
    Wouter Plattel
    Stefano Rosati
    Estella Matutes
    Marcel Nijland
    Annals of Hematology, 2022, 101 : 703 - 704
  • [37] A case of atypical hairy cell leukemia variant.
    Johnson, NA
    Warner, M
    BLOOD, 2002, 100 (11) : 283B - 283B
  • [38] Molecular variant of hairy cell leukemia with poor prognosis
    Arons, Evgeny
    Kreitman, Robert J.
    LEUKEMIA & LYMPHOMA, 2011, 52 : 99 - 102
  • [39] Translocation (1;14) in hairy cell leukemia variant
    Bayrak, A.
    Ucur, A.
    Satkin, B.
    Palanduz, S.
    Karan, M.
    Ozturk, S.
    Cefle, K.
    CHROMOSOME RESEARCH, 2009, 17 : 162 - 162
  • [40] Treatment of hairy cell leukemia-variant with cladribine
    Tetreault, SA
    Robbins, BA
    Saven, A
    LEUKEMIA & LYMPHOMA, 1999, 35 (3-4) : 347 - +